Company intelligence / Profile preview
CORXEL Pharmaceuticals
Berkeley Heights, New Jersey, United Statescorxelbio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
CORXEL has multiple late-stage clinical programs. Their CX11 program received FDA clearance for a Phase 2 trial for obesity in April 2025. Their LNZ100 program met its primary endpoint in a Phase 3 trial for presbyopia in China with 74% of participants achieving three-lines or greater improvement. Varenicline solution nasal spray received NMPA approval in China for dry eye disease in November 2024.
- Therapeutic areas
- CardiovascularOphthalmologyEndocrinology
- Modalities
- Small moleculesGLP-1 receptor agonists
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
VincentageLENZ TherapeuticsPatheon Inc.
Beyond the preview
Go deeper on CORXEL Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CORXEL Pharmaceuticals.